Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes

Carol B Toris, M. E. Tafoya, C. B. Camras, M. E. Yablonski

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Purpose: The mechanism by which apraclonidine, an α2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans. Methods: In a randomized, double-masked, placebo-controlled study, 0.5% apraclonidine was given topically twice daily for 1 week to one eye in each of 21 ocular hypertensive volunteers. The other eye was treated similarly with vehicle. Before and after 1 week of treatment, aqueous flow, uveoscleral outflow, fluorophotometric outflow facility, intraocular pressure, tonographic outflow facility, episcleral venous pressure, and outflow pressure were either directly measured or mathematically calculated. Values were compared in treated versus contralateral control eyes and on baseline versus day 8 of treatment. Results: When compared with both contralateral control eyes and baseline day, fluorophotometric outflow facility in the apraclonidine-treated eyes increased by 0.09 to 0.10 μl/minute/mmHg (P < 0.04), IOP decreased by 3.1 to 5.2 mmHg (P < 0.0001), and outflow pressure decreased by 3.3 to 4.2 mmHg (P < 0.0001). When compared with baseline day only, aqueous flow in the apraclonidine-treated eyes decreased by 0.3 μl/minute (P < 0.04), and episcleral venous pressure decreased by 1.0 mmHg (P < 0.001). Episcleral venous pressure also decreased in the control eyes compared with baseline day by 1.3 mmHg (P < 0.001 ). When compared with contralateral control eyes only, uveoscleral outflow in the apraclonidine-treated eyes decreased by 0.47 μl/minute (P < 0.03). Tonographic outflow facility showed no change when compared with either contralateral control eyes or baseline values. Conclusions: The apraclonidine-induced reduction in intraocular pressure was associated with an increase in fluorophotometric outflow facility, decrease in aqueous flow and decrease in episcleral venous pressure compared to baseline. The lack of a significant difference in aqueous flow and episcleral venous pressure between treated and contralateral control eyes may represent a contralateral drug effect.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
JournalOphthalmology
Volume102
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Aqueous Humor
Venous Pressure
Intraocular Pressure
apraclonidine
Pressure
Adrenergic Agonists
Volunteers
Placebos

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes. / Toris, Carol B; Tafoya, M. E.; Camras, C. B.; Yablonski, M. E.

In: Ophthalmology, Vol. 102, No. 3, 01.01.1995, p. 456-461.

Research output: Contribution to journalArticle

Toris, Carol B ; Tafoya, M. E. ; Camras, C. B. ; Yablonski, M. E. / Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes. In: Ophthalmology. 1995 ; Vol. 102, No. 3. pp. 456-461.
@article{93368958c66e4e5fbd12045d3335f21a,
title = "Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes",
abstract = "Purpose: The mechanism by which apraclonidine, an α2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans. Methods: In a randomized, double-masked, placebo-controlled study, 0.5{\%} apraclonidine was given topically twice daily for 1 week to one eye in each of 21 ocular hypertensive volunteers. The other eye was treated similarly with vehicle. Before and after 1 week of treatment, aqueous flow, uveoscleral outflow, fluorophotometric outflow facility, intraocular pressure, tonographic outflow facility, episcleral venous pressure, and outflow pressure were either directly measured or mathematically calculated. Values were compared in treated versus contralateral control eyes and on baseline versus day 8 of treatment. Results: When compared with both contralateral control eyes and baseline day, fluorophotometric outflow facility in the apraclonidine-treated eyes increased by 0.09 to 0.10 μl/minute/mmHg (P < 0.04), IOP decreased by 3.1 to 5.2 mmHg (P < 0.0001), and outflow pressure decreased by 3.3 to 4.2 mmHg (P < 0.0001). When compared with baseline day only, aqueous flow in the apraclonidine-treated eyes decreased by 0.3 μl/minute (P < 0.04), and episcleral venous pressure decreased by 1.0 mmHg (P < 0.001). Episcleral venous pressure also decreased in the control eyes compared with baseline day by 1.3 mmHg (P < 0.001 ). When compared with contralateral control eyes only, uveoscleral outflow in the apraclonidine-treated eyes decreased by 0.47 μl/minute (P < 0.03). Tonographic outflow facility showed no change when compared with either contralateral control eyes or baseline values. Conclusions: The apraclonidine-induced reduction in intraocular pressure was associated with an increase in fluorophotometric outflow facility, decrease in aqueous flow and decrease in episcleral venous pressure compared to baseline. The lack of a significant difference in aqueous flow and episcleral venous pressure between treated and contralateral control eyes may represent a contralateral drug effect.",
author = "Toris, {Carol B} and Tafoya, {M. E.} and Camras, {C. B.} and Yablonski, {M. E.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0161-6420(95)31000-7",
language = "English (US)",
volume = "102",
pages = "456--461",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes

AU - Toris, Carol B

AU - Tafoya, M. E.

AU - Camras, C. B.

AU - Yablonski, M. E.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Purpose: The mechanism by which apraclonidine, an α2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans. Methods: In a randomized, double-masked, placebo-controlled study, 0.5% apraclonidine was given topically twice daily for 1 week to one eye in each of 21 ocular hypertensive volunteers. The other eye was treated similarly with vehicle. Before and after 1 week of treatment, aqueous flow, uveoscleral outflow, fluorophotometric outflow facility, intraocular pressure, tonographic outflow facility, episcleral venous pressure, and outflow pressure were either directly measured or mathematically calculated. Values were compared in treated versus contralateral control eyes and on baseline versus day 8 of treatment. Results: When compared with both contralateral control eyes and baseline day, fluorophotometric outflow facility in the apraclonidine-treated eyes increased by 0.09 to 0.10 μl/minute/mmHg (P < 0.04), IOP decreased by 3.1 to 5.2 mmHg (P < 0.0001), and outflow pressure decreased by 3.3 to 4.2 mmHg (P < 0.0001). When compared with baseline day only, aqueous flow in the apraclonidine-treated eyes decreased by 0.3 μl/minute (P < 0.04), and episcleral venous pressure decreased by 1.0 mmHg (P < 0.001). Episcleral venous pressure also decreased in the control eyes compared with baseline day by 1.3 mmHg (P < 0.001 ). When compared with contralateral control eyes only, uveoscleral outflow in the apraclonidine-treated eyes decreased by 0.47 μl/minute (P < 0.03). Tonographic outflow facility showed no change when compared with either contralateral control eyes or baseline values. Conclusions: The apraclonidine-induced reduction in intraocular pressure was associated with an increase in fluorophotometric outflow facility, decrease in aqueous flow and decrease in episcleral venous pressure compared to baseline. The lack of a significant difference in aqueous flow and episcleral venous pressure between treated and contralateral control eyes may represent a contralateral drug effect.

AB - Purpose: The mechanism by which apraclonidine, an α2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans. Methods: In a randomized, double-masked, placebo-controlled study, 0.5% apraclonidine was given topically twice daily for 1 week to one eye in each of 21 ocular hypertensive volunteers. The other eye was treated similarly with vehicle. Before and after 1 week of treatment, aqueous flow, uveoscleral outflow, fluorophotometric outflow facility, intraocular pressure, tonographic outflow facility, episcleral venous pressure, and outflow pressure were either directly measured or mathematically calculated. Values were compared in treated versus contralateral control eyes and on baseline versus day 8 of treatment. Results: When compared with both contralateral control eyes and baseline day, fluorophotometric outflow facility in the apraclonidine-treated eyes increased by 0.09 to 0.10 μl/minute/mmHg (P < 0.04), IOP decreased by 3.1 to 5.2 mmHg (P < 0.0001), and outflow pressure decreased by 3.3 to 4.2 mmHg (P < 0.0001). When compared with baseline day only, aqueous flow in the apraclonidine-treated eyes decreased by 0.3 μl/minute (P < 0.04), and episcleral venous pressure decreased by 1.0 mmHg (P < 0.001). Episcleral venous pressure also decreased in the control eyes compared with baseline day by 1.3 mmHg (P < 0.001 ). When compared with contralateral control eyes only, uveoscleral outflow in the apraclonidine-treated eyes decreased by 0.47 μl/minute (P < 0.03). Tonographic outflow facility showed no change when compared with either contralateral control eyes or baseline values. Conclusions: The apraclonidine-induced reduction in intraocular pressure was associated with an increase in fluorophotometric outflow facility, decrease in aqueous flow and decrease in episcleral venous pressure compared to baseline. The lack of a significant difference in aqueous flow and episcleral venous pressure between treated and contralateral control eyes may represent a contralateral drug effect.

UR - http://www.scopus.com/inward/record.url?scp=0028931269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028931269&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(95)31000-7

DO - 10.1016/S0161-6420(95)31000-7

M3 - Article

C2 - 7891985

AN - SCOPUS:0028931269

VL - 102

SP - 456

EP - 461

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 3

ER -